(1R,3S-)Solifenacin-d5 Hydrochloride

Solifenacin-d5 Hydrochloride is a synthetic antimuscarinic medication used to treat symptoms of overactive bladder such as urinary frequency, urgency, and urge incontinence. The drug works by blocking acetylcholine receptors in the bladder, which reduces muscle contractions and increases bladder capacity. Solifenacin-d5 Hydrochloride is administered orally in tablet form, and the recommended dosage is typically 5-10 mg daily. The chemical structure of Solifenacin-d5 Hydrochloride is based on the parent compound Solifenacin, with the addition of five deuterium atoms to replace hydrogen atoms at specific positions. This modification allows for precise measurement of the drug's metabolism and pharmacokinetics in clinical studies. The hydrochloride salt form of Solifenacin-d5 Hydrochloride is a white to off-white crystalline powder that is soluble in water and ethanol. Its chemical formula is C23H26D5NO4.HCl, and its molecular weight is 442.01 g/mol. Solifenacin-d5 Hydrochloride is metabolized in the liver by cytochrome P450 enzymes, primarily CYP3A4 and CYP2D6. Its elimination half-life is approximately 45 hours, and it is excreted in the urine and feces. While Solifenacin-d5 Hydrochloride is generally well-tolerated, common side effects include dry mouth, constipation, blurred vision, and urinary retention. Patients with narrow-angle glaucoma, severe liver or kidney impairment, or urinary retention should not take Solifenacin-d5 Hydrochloride.